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Objective. We evaluated histological outcome of intraoperative biopsies at laparoscopic renal mass cryoablation (LCA), prevalence
of peritumoral fat tissue invasion, and risk of tract seeding. Methods. Patients were biopsied 3–5 times (16-gauge). Histology was
analyzed by general pathologists and reviewed. Peritumoral fat was histologically examined. The trocar used for biopsy-guidance
was examined by cytology. Records were studied for reporting tract metastasis. Results. 77 biopsied renal masses with mean ± SD
diameter 30± 7.4mm were histologically classified by primary and review pathology revealing 64 and 62 malignancies, 13 and 15
benign lesions, respectively. In 30/34, the fat covered a carcinoma but revealed no malignancy. Cytology showed no malignant cells
but was inconclusive in 1 case. No tract metastasis occurred. Conclusions. The use of an intraoperative biopsy protocol provides
histological diagnosis of all renal masses. No existence of peritumoral fat tissue invasion or tract seeding was found.
1. Introduction
The incidence of small renal tumors increases. More often
these asymptomatic lesions are coincidentally found with
cross-sectional imaging [1, 2]. Currently, the indication
for surgical treatment of small renal masses is specifically
based on radiographic imaging features, such as a consistent
appearance and contrast enhancement [3]. However, tumor
size and imaging alone are poor indicators for predicting
the biological nature of the lesion [4–8]. Promising steps
towards objectifying the relationship between radiological
tumor anatomy and pathology were recently showed by
Kutikov et al. [9], using the RENAL nephrometry score and
the histology and grade of resected tumors.
The biological potential of small renal cell carcinomas
(RCC) seems to be mild. This reflects in the relative mer-
it cancer-specific survival of stage 1 disease [10]. However,
it is stated that lesions of 3-4 cm diameter have a signif-
icant higher risk for high-grade and advanced-stage disease
compared to smaller lesions [11]. Analysis of the Surveillance
Epidemiology and End Results database suggested that
stage 1 low-grade and high-grade RCC may appear in a
more aggressive behaviour, in elderly patients, resulting
in an increased cancer-specific mortality rate [10]. Today,
urologists are increasingly faced with early-stage asymp-
tomatic patients also having a renal mass ≤4 cm of potential
malignancy. The majority is diagnosed in elderly patients
bearing comorbidities that influence treatment decisions
[12]. Especially, counselling this group of patients in the con-
text of uncertain tumor pathology and biological potential
remains a challenge.
Possible ways to avoid unnecessary, invasive treatment
would be the use of diagnostic markers or to determine
histology with image-guided core needle biopsies. How-
ever, the use of markers predicting the biological nature
of renal masses ≤4 cm has not extensively been tested
and validated. Although there is evidence that computed-
tomography-guided percutaneous biopsies can help to dis-
tinguish between benign andmalignant tissue, this method is
not routinely used [13]. Hence, arguments such as sampling
errors and possible track seeding are used to favor the risk of
surgery in ignorance of histological diagnosis.
Currently, nephron-sparing surgery (NSS) is mandated
for the invasive treatment of small renal masses. Among
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the various techniques qualifying the values of NSS, the par-
tial nephrectomy is considered as the golden standard [14].
Laparoscopic partial nephrectomy is especially recognized
for its challenging surgical skills and significant morbidity
rate. Laparoscopic renal cryoablation (LCA) overcomes some
of these shortcomings and is, therefore, gaining importance
in the last decade.
The major limitation of LCA is the lack of tumor
extirpative histology. So far, staging and follow-up pattern
are based solely on the histological findings obtained by
biopsy. Biopsies are performed image-guided preoperative
or laparoscopic-assisted intraoperatively. Neither way the
accuracy of the biopsy can be verified. Furthermore, staging
is incomplete because biopsy specimen is not eligible for
studying capsular or perirenal fat invasion. The last would
stage a tumor ≤4 cm up from pT1a to pT3a according to
the definition of the 7th TNM classification 2010 and is
considered as a poor prognostic factor.
Another limitation of LCA is the analysis of long-
term data on the oncological outcome. This can only be
done if the histological nature of the treated masses is
identified. However, limited reports reveal their malignant
or benign nature of LCA-treated lesions. Often they show a
significant percentage of benign and nondiagnostic biopsies.
The RCC subtype and nuclear-grade diﬀerentiation are
rarely mentioned. Furthermore, often the malignancy rate
is lower than one would expect when comparing the rate
to studies that report histology of renal masses obtained by
extirpative surgery [8]. The role of materials and method of
intraoperative biopsies needs to be studied.
For these above-mentioned limitations, the objective of
this study was to evaluate the histological outcome of an
intraoperative core needle biopsy protocol practiced at the
time of LCA for small renal masses. The protocol should
prevail in a small nondiagnostic rate and a malignancy
rate that is comparable to series reporting on extirpation
histology. We investigated also the existence of perinephric
fat tissue invasion. Finally, the potential risk of tract seeding
due to needle biopsy was analyzed.
2. Patients and Methods
From 2007 to August 2011, all patients with small renal
masses treated with LCA were used for this study. All
patients agreed with the intentions of the treatment. In a
laparoscopic procedure, the renal mass was visually identified
and confirmed with laparoscopic ultrasound.
The majority of the renal masses were exophytic. Critical
point in the cryosurgical procedure was a staunch dissection
of the tumor allowing identification of the lesion and its
border. When the perirenal fat appeared to be denser and
more adhesive to the tumor capsule, it was dissected and
sampled for histological examination.
All renal masses were biopsied intraoperatively before
cryoprobe placement. Laparoscopic ultrasound was used
to avoid biopsies from cystic or necrotic parts in the
lesions. For tissue sampling, we used a Magnum biopsy gun
(Bard, Covington, Lousiana, USA), loaded with a disposable
16-gauge automatic side-cutting biopsy needle with a sample
notch range of 19mm. The device was fired through a trocar
with the open end of the trocar close to the target. The biopsy
needle was used percutaneously in case the distance through
the trocar to the target was too long for reaching it properly.
Trocar that was used for guidance of the biopsy needle
was removed, rinsed, and submerged in saline. The saline
was cytologically examined to determine the existence of
tumor cells. Retrospectively, all patient records were studied
for reporting metastasis in the tract of trocar, biopsy, and
cryoprobe placement.
A standard of 3 biopsies were taken at diﬀerent locations
in the mass. The biopsy specimen was loaded oﬀ the needle
on a glossy-coated paper surface. This method enabled to
determine the value of all specimen obtained. More biopsies,
with a maximum of 5, were taken when the value of 1 or
more of the first 3 biopsies was considered to be limited at
macroscopic inspection by the surgeon. Finally, all specimens
were submerged in formalin. The biopsy and perirenal fat
specimens were examined after normal hematoxylin and
eosin (H&E) staining. If needed, on the biopsy specimen;
immunohistochemical (IHC) staining (CD-10, CD-15, CD-
117, CK-7, CK-20, Vimentin) was used to accept or to attain
final diagnosis.
The first histology reports of the biopsies and perirenal
fat were scored for the diagnosis indicating malignant or
benign tissue. Tumor histology and subtype were reported
according to the WHO 2004 classification (Bostwick and
Cheng, 2008) [15]. The Fuhrman nuclear grade (1 to
4) was scored. To study the interobserver variability, two
experienced uropathologists, ignorant for the goals of this
study and the preliminary results of histology, reviewed the
entire series of biopsies. The interobserver agreement on the
lesions being malignant or not was calculated using Cohen
kappa coeﬃcient.
3. Results
A total of 81 LCA procedures on 80 small renal masses were
carried out in 79 patients. Patient and tumor characteristics
are shown in Table 1. One patient was treated for two lesions
in the same kidney each in diﬀerent operative sessions. 3
patients, of whom preoperative histological biopsies were
proven to be malignant, were excluded. In 1 case, the tumor
ablation was not completed as found at first evaluation using
contrast computed-tomography (CT) and, thus, underwent
a second LCA. The repeat biopsy was excluded from the study
but revealed vital cells of the same clear cell carcinoma as
found in the first procedure. In 3/81 (3.7%), the laparoscopic
procedure was converted to an open cryoablative procedure.
Extreme thick and adhesive perirenal fat prohibited a safe
exposure without harming the kidney and the tumor and
precluded an accurate targeting and, therefore, cryoablation.
They remained included in the study because the biopsies
were obtained according to the protocol. In total, 77 renal
masses, with a mean ± SD diameter 30 ± 7.4mm (range
15 to 50mm), were intraoperatively biopsied. All tumors,
as assessed by preoperative CT-scan and confirmed by
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Table 1: Patient and tumor characteristics.
Patients (n)
Male 55
Female 24
Patient age (yr) (range) 65,9 (36–83)
Mean (SD yr) 68 (10.6)
Kidney (n)
Right 46
Left 35
Indications (n)
Solitary kidney 7
Tumor recurrence 1
2nd tumor ipsilateral kidney 1
Other 72
Tumors (n) 78
Tumor size (mm) (range) 30,6 (15–50)
Mean (SD mm) 30 (7.6)
LCA approach (n)
Retroperitoneal 46
Transperitoneal 35
Conversion 3
laparoscopic ultrasound, were solid and round of form
except for two cystic lesions that were classified as Bosniak
III lesions.
All intraoperative biopsied renal masses were histologi-
cally classified. In total, 64 renal cortical cancers (83%) and
13 benign lesions (17%) were diagnosed. In 2 cases (2.6%),
the biopsy specimens were diagnosed as renal cancer, but a
subtype could not be specified. All malignancies showed no
association with patient oncological history or transitional
cell carcinoma. Both cystic lesions represented RCC. After
review of the series, the blinded pathologists assessed 62
malignancies (80%) and 15 benign lesions (20%). Table 2
shows the pathological characteristics from primary and
review pathology. Table 3 shows the interobserver agreement
on a tumor being malignant or not. The relative observed
agreement was (62 + 13)/77 = 0.974, and hypothetical
probability of change agreement was {(64/77) × (62/77)} +
{(13/77) × (15/77)} = 0.702. The Cohen kappa coeﬃcient
for this was (0.974 − 0.702)/(1 − 0.702) = 0.913. The
reviewing pathologists agreed in 95% of the cases with the
initial specification of the subtype of malignant or benign
lesion. A discrepancy was noted in 4 cases as is specified in
Table 4. In 47 cases where agreement was found between
the observers considering the RCC subtype, both primary
as review pathology assessed the nuclear grade. Agreement
was found in 19 cases (40%). In 27 cases, the reviewing
pathologists assessed the nuclear grade 1 to 2 grades higher
and in 1 case (2%) 1 grade under.
Dense and adhesive peritumoral fat was specifically
found in men 31/34 (91%). In 30/34 (88%), the fat covered
a proven carcinoma (mean ± SD diameter 33 ± 7mm, range
19–50mm). Histology did not reveal malignancy in all cases.
Cytology of the saline rinsed over the trocars was assessed
Table 2: Pathological characteristics of 77 intraoperatively biopsied
renal masses.
Histology
Primary pathology
(n)
Review pathology
(n)
Renal cell carcinoma
Clear cell 43 41
Papillary 11 13
Chromophobe 8 8
Undefined 2
Angiomyolipoma 3 3
Oncocytoma 10 12
Table 3: Interobserver agreement on renal masses diagnosed
malignant or benign. Observer 1 represents the primary diagnosis
by general pathologists. Observer 2 represents the diagnosis as
determined by the blinded review pathologists.
Observer 1
benign malignant
Total
observer 2
Observer 2
benign 13 2 15
malignant O 62 62
Total observer 1 13 64 77
Table 4: Specifications of 4 subtype diagnoses that were diﬀerently
scored by primary pathology and review pathology. RCC: renal cell
carcinoma.
Primary diagnosis Review uropathologists diagnosis
RCC not specified oncocytoma
Clear cell RCC oncocytoma
RCC not specified papillary RCC
Clear cell RCC papillary RCC
in 33 biopsied tumors, of which 27 biopsied lesions were
malignant. It showed a variety of cellular types such as blood,
muscular, epithelial, and fat cells. In 1 case, cells could not be
classified and were unsure of RCC origin. However, during
followup (8 months), no sign of tract metastasis occurred.
In all cases of RCC, with a mean followup period of 24
months (range 1–57 months), there was no existence of tract
metastasis on physical examination or contrast CT-scan.
4. Discussion
The role of ordinary image-guided biopsies of a renal mass
prior to intervention or during followup was not within
the scope of this study. Within the context of that almost
20% of renal masses <4 cm will be benign [8, 16], it is not
just that patients remain refrained from a final diagnosis
after surgical treatment indented for a suspected malignancy.
Besides the psychological importance for patients, several
arguments support the need for an improved indexation of
the biological nature of LCA-treated tumors. Although this
method is currently a well-accepted treatment option, large
series of long-term data are insuﬃcient and final histology is
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often not reported. So far, the majority of the literature has
focused more on the technical success based on follow-up
imaging rather than combining it with histological diagnosis.
This implicates that the clinical eﬃcacy and success rate of
cryosurgery as focal treatment of RCC cannot be objectified.
Furthermore, the necessity and intensity of follow up using
contrast radiographic imaging cannot be adjusted. So far,
a risk-adapted followup has not been introduced in the
literature. Unfortunately, there is no consensus on the follow-
up of ablated small renal masses. This study shows a high
interobserver agreement on the histological findings. There-
fore, we consider that pathology findings of intraoperatively
obtained biopsies can be used for adjustments of the routine
followup.
This study is limited by a relatively small sample size,
but it suggests that histological diagnosis can be obtained
performing intraoperative core needle biopsies of a small
renal mass prior to LCA. Sample errors are expected to be
rare when biopsies are performed under direct laparoscopic
vision and ultrasound guidance. In all cases, the biopsy
strategy provided in enough tissue capacity for normal H&E
and occasional IHC staining and resulted in a histological
diagnosis. Furthermore, this study shows that there was no
significant diﬀerence between the primary pathology and the
review pathology by general pathologists and uropathologist,
respectively.
Studies of LCA series that, also reported histology,
showed a variation in malignancy percentage, normal renal
tissue percentage, unclassified diagnosis rate, and benign
tissue percentage [17–22]. Themalignancy rate of 80% found
in this study was higher compared to other LCA series.
The malignancy rate of this study was in line with the
expected malignancy rate reported in studies of small renal
masses treated with extirpative surgery [8, 16]. Factors such
as patient selection, tumor size, age, and biopsy quality
may aﬀect the undiagnosed rate and malignancy rate. The
influence of patient selection will not be discussed.
It is reported that malignancy rate appears to be related
to renal mass diameter [4, 6–8, 20, 23]. In this study, we
noted that the mean renal mass diameter of 30mm was
larger compared to much other histology reporting LCA
series in the literature (range 24–29mm) [17–22], which
may explain the higher malignancy rate. In this study, after
primary pathology assessment, we found an increase of
malignancy rate from 79% to 87% for lesions ≤3 cm and
>3 cm, respectively. In general, patients with a maximal
tumor diameter of 4 cm are oﬀered cryoablation. However, at
our referral centre for small renal masses, sometimes patients
are presented with a renal mass >4 cm diameter mandating
minimally invasive and nephron-sparing treatment. When
all lesions >4 cm (n = 7) were excluded from this study, the
malignancy rate was 80%. However, the mean ± SD tumor
diameter remained 29 ± 5.9mm, which may explain the
higher malignancy rate.
Also, patient’s age at the time of surgery can alter the
malignancy rate [24]. It is stated that younger patients have a
higher probability of bearing a malignancy. The average age
in this study was 65,9 years, which was equivalent to most
other series and, thus, other factor(s) than age must have
caused the higher malignancy rate [17–19, 22]. However,
comparing the data to Lehman et al. [20], we noticed that
in both cohorts (≤3 cm and >3 cm) the mean age in this
study was almost 10 years younger. Therefore, the lower
malignancy rates (46.7% and 66.7%, resp.) found by Lehman
et al. [20] at least need to be corrected for the factor age.
Hence, for the other series another component must have
caused the diﬀerence.
Several studies discussed the relationship between the
amount of biopsy specimen and diagnosis rate [25, 26].
Johnson et al. [25] analyzed the results of sonograph-
ically guided renal mass biopsy and showed that using
an 18-gauge core needle revealed more reliable diagnostic
results compared to using a 20-gauge core needle. Kramer
et al. [26] showed clearly that by increasing the number
of intraoperative biopsy cores from 1 to 3 at LCA, the
malignancy rate increased from 60% to 71%, whereas the
nondiagnostic rate decreased from 17% to 5%. The protocol
of minimal 3 biopsies using a 16-gauge needle with a sample
notch range of 19mm provided an excellent tissue sample
size, which to our opinion was related to our high diagnosis
rate.
This study is limited by the absence of histological
confirmation because all tumors were ablated and not extir-
pated. Consequently, the false negative or positive rate and
nuclear up- or downgrading of malignancies is unknown.
The accuracy of the histology can only be examined in a
prospective study comparing intraoperative biopsies to the
histology of the extirpated lesion. We are not aware of a
study with this design. Schmidbauer et al. [13] reported
on the diagnostic accuracy of preoperative biopsies. They
compared the histology of 2 or 3 18-gauge core needle CT-
guided preoperative biopsies to that of the final extirpation
specimen. The sensitivity for RCC detection was 93.5%. 2
sets of biopsies (3%)missed the target and were false negative
showing normal renal parenchyma, whereas final histology
revealed clear cell carcinoma. In a MEDLINE search, Volpe
et al. [27] found that, at centers with expertise, an accurate
diagnosis for malignancy was obtained in more than 90%
of the percutaneous renal mass biopsies. Objectively, there
is no reason to suppose that intraoperative biopsies are
less accurate than percutaneous biopsies. Although some
malignant subtypes are limited and diﬃcult to discern or
remain unclassified, this is not expected to account for a
nondiagnostic rate >10% [28]. These data support that if
biopsies are targeted appropriately and enough qualitative
tissue is sampled an accurate histological diagnosis can be
assessed.
Subtype, stage, and grade may help to predict small renal
cancer-specific survival [4, 6, 8, 11]. Biopsy histology may
require in a subtype diagnosis, but true staging remains
incomplete, which is a limitation. Assessment of peritumoral
fat invasion of small renal cancers would be helpful. So far,
this study showed no invasion of peritumoral fat, but the
data was biased by patient selection. However, in partial
nephrectomy also tissue extirpation including perirenal fat is
not standard. We recognize that the sample size of this study
was limited and will continue to collect more data.
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Schmidbauer et al. [13] found a nuclear grade accuracy
rate of 76% determined in percutaneous biopsy specimen.
This study revealed an interobserver agreement of 39%
for the nuclear grade. However, the accuracy cannot be
studied by the lack of conclusive histology of extirpated
tumors. Nuclear grade is a characteristic used in preoperative
prognostic nomograms for partial nephrectomy [29]. When
in future nomograms for LCA may be developed, the role
of nuclear grade based on biopsy specimen needs to be
discussed.
The overall estimated risk for tract seeding due to percu-
taneous biopsies is <0.01% [30]. To our knowledge, no track
seeding in LCA has been reported. The limited data of this
study supported that there is no increased risk for seeding
in LCA alongside the tracks of trocars, percutaneous biopsy,
and percutaneous cryoprobes. However, the discovery of cells
of uncertain RCC-origin supports us to continue sampling
data of trocar cytology to assess further the potential risk of
seeding.
The focus of this paper was not on complications of
intraoperative biopsies. Today, there is no study reporting
complications of intraoperative renal biopsies. However,
image-guided diagnostic biopsies have a low complication
rate of which bleeding is most frequently reported. In our
series, bleeding was minimal and could be taken care of
during surgery. So far, in our series of renal mass LCA,
we did not encounter a high rate of complications. The
complication rate is 17% (Clavien-score 1-3a), which is
comparable to the reported complication rates of renal mass
LCA in the literature.
5. Conclusions
The intraoperative biopsy protocol for small renal masses
provided histological diagnosis with a high-interobserver
concordance for the RCC-subtype and avoided unnecessary
nondiagnostic biopsies. The malignancy rate of 80% was
comparable to series reporting on extirpative histology. No
existence of peritumoral fat tissue invasion was found. Tract
seeding in LCA did not exist. Further studies are needed to
improve staging of small renal masses treated with LCA.
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